This grant has a simple philosophy: a powerful method to approach neurodegenerative disease is (1) use molecular genetics to identify the genes involved in their etiology, with the expectation that these genes will mark a biochemical pathway to disease (2) use the techniques of cell biology and transgenics to try and dissect this pathway and to try and develop cellular and animal models of elements of the disease process. In this proposal, we apply these techniques (predominantly) to Lewy Body Parkinson's disease. It is clear that there are more than three genes involved in the etiology: first, the alpha-synuclein gene, second, an as-yet-unidentified gene on chromosomes 2p and third, an as yet unidentified gene on chromosome 4p: both of these latter two genes have been """"""""linked"""""""" by this group. In addition to these known and localized genes, many families do not show linkage to any of the known loci, implying that there are others to be found. With this philosophy and progress as """"""""background"""""""", we have the following major aims: Project, to clone the gene on chromosome 4p: Project, to clone the gene on chromosome 2p: Project, to make overexpressing wild type and mutant alpha-synuclein mice with the longterm goal of mimicking parts of the human disease process, and """"""""knockout"""""""" mice to aid in the understanding of synuclein function. Projects will encompass similar analyses of the ch4p and ch2p genes and their products as they are identified. These projects will be co-ordinated through an Administrative Core and grouped around a Clinical/pathological Core, which will be responsible for family ascertainment and human blood and brain sample collection and for the pathological verification of diagnosis in both family members and in transgenic animals and a Linkage Core which will be responsible for distributing human family material into four """"""""bins"""""""": """"""""mutation Known"""""""", """"""""ch4p linked"""""""" """"""""ch2p linked and """"""""presently unlinked"""""""".

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
5P01NS040256-05
Application #
6644878
Study Section
Special Emphasis Panel (ZAG1-PKN-2 (O2))
Program Officer
Murphy, Diane
Project Start
1999-09-30
Project End
2004-09-29
Budget Start
2003-08-01
Budget End
2004-09-29
Support Year
5
Fiscal Year
2003
Total Cost
$1,242,296
Indirect Cost
Name
Mayo Clinic, Jacksonville
Department
Type
DUNS #
153223151
City
Jacksonville
State
FL
Country
United States
Zip Code
32224
Yue, M; Hinkle, K M; Davies, P et al. (2015) Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis 78:172-95
Sundal, Christina; Fujioka, Shinsuke; Van Gerpen, Jay A et al. (2013) Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. Parkinsonism Relat Disord 19:869-77
Boeve, Bradley F (2013) Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol 12:469-82
Fujioka, Shinsuke; Rayaprolu, Sruti; Sundal, Christina et al. (2012) A novel de novo pathogenic mutation in the CACNA1A gene. Mov Disord 27:1578-9
Hinkle, Kelly M; Yue, Mei; Behrouz, Bahareh et al. (2012) LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol Neurodegener 7:25
Graff-Radford, Jonathan; Whitwell, Jennifer L; Trenerry, Max R et al. (2011) Focal brain atrophy in gastric bypass patients with cognitive complaints. J Clin Neurosci 18:1671-6
Puschmann, Andreas; Wszolek, Zbigniew K (2011) Diagnosis and treatment of common forms of tremor. Semin Neurol 31:65-77
Winner, B; Melrose, H L; Zhao, C et al. (2011) Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis 41:706-16
Angeles, Dario C; Gan, Bong-Hwa; Onstead, Luisa et al. (2011) Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum Mutat 32:1390-7
Finch, N; Carrasquillo, M M; Baker, M et al. (2011) TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 76:467-74

Showing the most recent 10 out of 71 publications